New drug combo PrimeC shows promise in slowing ALS
Disease control
Completed
This phase IIb trial tested PrimeC, a combination of two common drugs (ciprofloxacin and celecoxib), in 69 people with ALS. Participants took PrimeC or a placebo for 6 months, followed by a 12-month open-label extension where everyone received PrimeC. The study measured safety, s…
Phase: PHASE2 • Sponsor: NeuroSense Therapeutics Ltd. • Aim: Disease control
Last updated Jun 26, 2026 14:14 UTC